Milestone Pharmaceuticals Inc Total Assets
Milestone Pharmaceuticals Inc total assets. Based on the latest financial reports, Milestone Pharmaceuticals Inc (MIST) holds total assets worth $87.75 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see MIST market cap for the company's overall valuation and market capitalisation.
Total Assets of Milestone Pharmaceuticals Inc (2017–2024)
Total assets of Milestone Pharmaceuticals Inc from 2017 to 2024. This chart illustrates how Milestone Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See current stock price of Milestone Pharmaceuticals Inc for real-time trading data and today's change.
Milestone Pharmaceuticals Inc - Asset Composition Analysis
Milestone Pharmaceuticals Inc Total Assets Breakdown (December 2024)
Milestone Pharmaceuticals Inc total assets breakdown as of December 2024. Milestone Pharmaceuticals Inc's total assets of $87.75 Million consist of 97.9% current assets and 2.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 33.5% |
| Accounts Receivable | $2.39 Million | 3.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Milestone Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Milestone Pharmaceuticals Inc's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Milestone Pharmaceuticals Inc's current assets represent 97.9% of total assets in 2024, a decrease from 99.9% in 2017.
- Cash Position: Cash and equivalents constituted 33.5% of total assets in 2024, down from 39.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 3.2% of total assets.
Milestone Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Milestone Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Milestone Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.24 | 15.40 | 24.14 |
| Quick Ratio | 8.24 | 15.40 | 24.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $76.15 Million | $75.73 Million | $142.53 Million |
Milestone Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Milestone Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.31 |
| Latest Market Cap to Assets Ratio | 0.86 |
| Asset Growth Rate (YoY) | 0.4% |
| Total Assets | $75.50 Million |
| Market Capitalization | $64.67 Million USD |
Valuation Analysis
Near Book Valuation: The market values Milestone Pharmaceuticals Inc's assets close to their book value (0.86x), suggesting investors view the company's assets at approximately fair value.
Positive Asset Growth: Milestone Pharmaceuticals Inc's assets grew by 0.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Milestone Pharmaceuticals Inc (2017–2024)
The table below shows the annual total assets of Milestone Pharmaceuticals Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $75.50 Million | +0.36% |
| 2023-12-31 | $75.23 Million | +1.00% |
| 2022-12-31 | $74.48 Million | -37.85% |
| 2021-12-31 | $119.85 Million | -20.09% |
| 2020-12-31 | $149.97 Million | +21.51% |
| 2019-12-31 | $123.43 Million | +40.13% |
| 2018-12-31 | $88.08 Million | +219.25% |
| 2017-12-31 | $27.59 Million | -- |
About Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical tria… Read more